Select Health Care Portfolio

Fidelity Select Portfolios · 6 share classes

Actively managed U.S. equity fund
One fund, 6 share classes:FSPHXFHCQXFHCRXFHCLXFHCNXFHCPX
$5.78B NAV
152 positions · as of 2026-05-31 · filed 2026-07-24

Fund classification

Classified from what the fund holds · as of 2026 Q2

Select Health Care Portfolio is an actively managed U.S. equity fund.

Asset class
Equity
Region
United States
Management
Actively managed
Fund type
Open-end fund
Features
Non-diversified

Fund profile

As filed in the prospectus · 2026 Q2

Health Care Portfolio seeks capital appreciation.

Strategy · summarised

The fund invests at least 80% of assets in common stocks of companies principally engaged in health care and medicine, including biotechnology, pharmaceuticals, medical devices and equipment, and health care facilities and managed plans, using fundamental analysis of financial condition and industry position. The fund may invest in both domestic and foreign issuers. Because the fund's classification of companies as principally engaged in health care depends on factors such as asset levels, income, sales, or profits derived from designated activities, or on third-party industry classifications, the fund's holdings may diverge from what different analysts would consider core health care exposure.

Expenses
0.55% 1.66%across 6 share classes
Share classExpense ratioAs of
FSPHX0.62%2026 Q2
FHCQX0.66%2026 Q1
FHCRX0.55%2026 Q1
FHCLX0.91%2026 Q1
FHCNX1.16%2026 Q1
FHCPX1.66%2026 Q1

Portfolio turnover 69.00% · as of 2026 Q2

Allocation

Asset groups · long / short shown separately, never netted · 2026 Q2

102.19%
of net assets
Stocks99.69%
Cash & short-term2.36%
Bonds0.14%

Sector allocation

The same holdings as Allocation above, grouped by market sector instead of asset type · as of 2026 Q2

100%
of net assets
Health Care84.9%
International10.7%
Cash2.3%
Other1.9%
Industrials0.2%

Government, Securitized and Cash are non-corporate buckets; International is foreign holdings we don’t sector-classify, and Other is the residual (held funds, unresolved names).

Latest quarter

What changed since the fund's previous filing

2026Q2 vs 2026Q1: 39 new22 exited

Largest new: ASCENDIS PHARMA A/S, NTRA, VTRS, WST, A, JAZZ PHARMACEUTICALS PLC, ROCHE HOLDING AG, BRKR

Largest exited: ASCENDIS PHARMA A/S, MCK, ROCHE HOLDING AG, SYK, VEEV, CENTESSA PHARMACEUTICALS PLC, CYTK, BIONTECH SE

Return profile

Total return as filed — price change plus distributions reinvested · trailing figures to Apr 2026

1-year
+11.25%
3-year
+14.49%
5-year
+7.99%
Volatility
14.40%
Worst 3-yr fall
-13.59%
Cumulative return· Jun 2023 – Apr 2026

May 2026 has been filed since the trailing figures were struck, so it is not in the table above or the curve — every figure here shares one cut-off, which is what makes them comparable with other funds.

Debt profile

What this fund holds — value-weighted across its bond and securitized long positions · as of 2026-05-31

Avg coupon
0.07%
Avg maturity
0.63 yr
Coupon type

Share of the fund's debt by how its coupon behaves — the fact that decides whether a rate move reaches this portfolio at all.

29%
floating
Fixed rate70.8%
Floating rate29.2%
Maturity ladder

Share of the fund's debt value in each maturity band, shortest first.

<1y10y+
<1y70.8%
10y+29.2%
Flagged holdings
Defaulted: none reported
In arrears: none reported
Paid in kind: none reported

Based on what filers reported; a filer that never reported a flag also reads as none.

Holdings

By % of NAV · equity positions carry filed share counts · every resolvable issuer links to its company page

Issuer%NAVValue
ELI LILLY and COLLY8.03%$464.10M
DANAHER CORPDHR6.89%$398.22M
JOHNSON and JOHNSONJNJ4.91%$283.92M
THERMO FISHER SCIENTIFIC INCTMO4.33%$250.20M
UNITEDHEALTH GROUP INCUNH3.49%$201.56M
ALNYLAM PHARMACEUTICALS INCALNY2.40%$138.91M
GILEAD SCIENCES INCGILD2.21%$127.71M
BOSTON SCIENTIFIC CORPBSX2.17%$125.61M
ASCENDIS PHARMA A/S2.17%$125.50M
Fidelity Revere Street Trust2.17%$125.45M
Showing 10 of 152Sign in to see more

Reported price is the fund's own reported value divided by its own reported shares at 2026-05-31 — not a live quote, and not what the fund paid.

Top 10 positions are 38.76% of net assets, top 25 59.59%, across 125 issuers.

See more of this fund's book

More positions with filed share counts, and the quarter-over-quarter change list rather than the largest few — free with an account, no card required.

Sign in free